Neopharma commenced operations in 2003 and the first set of manufacturing facilities were planned on an investment outlay of USD25 million. The organization’s inspiration stems from the vision to locally manufacture world class pharmaceuticals at affordable prices. Neopharmas global presence is supported by 5 manufacturing facilities spread across 3 continents delivering branded and generic formulations, and active pharmaceutical ingredients (APIs). The therapeutic segments covered by our portfolio of over 100 high-quality molecules include anti-infectives, neurology, cardiology, orthopedics, diabetology, gastroenterology, urology, dermatology, gynecology, respiratory, dental and nutritionals. Driven by innovation, Neopharma lays strong emphasis on research, especially towards development of processes and products that are patent non-infringing. Neopharma currently caters to over 50 international markets including Middle East, Africa, CIS, Far East and South East Asia.
This company has no news - if this is your company Login to add your first article
There are no reports available to view
Sustainability Data - Overview
How much data does Neopharma have available on ArabSustainability.com?
Compare Neopharma's sustainability performance
Inspect Data Compare to:
Sorry, there is no data for the indicator chosen. Please choose other parameters.